Acinetobacter News and Research

RSS

Altered microbiomes in SARS-CoV-2 infection pose threat of antibiotic resistance

A new study discusses changes in the microbiota of various parts of the body with SARS-CoV-2 infection.

27 Feb 2022

Structure of protein that can pump toxic molecules out of bacterial cells revealed

MIT chemists have discovered the structure of a protein that can pump toxic molecules out of bacterial cells. Proteins similar to this one, which is found in E. coli, are believed to help bacteria become resistant to multiple antibiotics.

18 Feb 2022

Research project receives additional funding to tackle a drug-resistant superbug

A global drive - led by University of the West of Scotland (UWS) - to tackle a drug-resistant superbug has received additional funding.

14 Feb 2022

New compound could combat multidrug-resistant pathogens in healthcare settings

For years, public-health experts have been sounding the alarm about the next phase in humanity's co-existence with bacteria-;a dark future where emerging strains have rendered once-powerful antibiotics useless.

5 Jan 2022

Cheap and accessible methods for genome sequencing will help tackle future pandemics

A worldwide consortium of scientists, led by the Earlham Institute and the University of Liverpool in the UK, mark a significant milestone in equipping researchers in low- and middle-income countries (LMICs) with cheap and accessible methods for sequencing large collections of bacterial pathogens - at a cost of less than $10USD per genome.

21 Dec 2021

Poolbeg and University College Dublin sign an Option Agreement to license melioidosis vaccine candidate

Poolbeg Pharma, 'Poolbeg' or the 'Company', a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin and its inventor, Associate Professor Siobhán McClean, through NovaUCD, the university's knowledge transfer office.

7 Dec 2021

Drug-resistant bacteria are quickly outpacing new antibiotic development

Experts predict that without intervention, the problem of multidrug-resistant bacterial infections could be catastrophic by 2050, killing nearly 10 million people each year.

24 Nov 2021

Machine learning approach effective in predicting antibiotic resistance spread

Genes aren't only inherited through birth. Bacteria have the ability to pass genes to each other, or pick them up from their environment, through a process called horizonal gene transfer, which is a major culprit in the spread of antibiotic resistance.

22 Oct 2021

GARDP, CHAI and Shionogi collaborate to accelerate access to antibiotic for bacterial infections

The Global Antibiotic Research and Development Partnership, the Clinton Health Access Initiative and Shionogi & Co., Ltd today announced a Memorandum of Understanding to accelerate access, including in low- and middle-income countries, to the antibiotic cefiderocol for bacterial infections in patients with limited treatment options.

13 Jul 2021

How do host factors like the lung microbiome aid in SARS‐CoV‐2 infection?

A new article has been published in Cellular and Molecular Lifesciences, which focuses on the connection between host factors and the worsening of the COVID-19. Further, the impact of the virus on the host’s microbiome and secondary infection has also been studied.

8 Jul 2021

Fish oil may help fight against superbugs

For the first time, Australian scientists have confirmed a link between the role of regular fish oil to break down the ability of 'superbugs' to become resistant to antibiotics.

9 Jun 2021

Centivax and US Naval Medical Research Center to begin Phase I clinical trial of antibody therapeutics

Centivax Inc. announced today that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) for Phase I clinical development of Centi-B9, Centivax's SARS-CoV-2 broad-spectrum injectable antibody therapeutic and prophylactic.

3 Jun 2021

Why COVID-19 patients have more pathogenic bacteria in their noses

Researchers compared the nasal microbiome of coronavirus disease 2019 (COVID-19) patients, healthy individuals, and healthcare workers. These studies indicated an increase in the pathogen Pseudomonas aeruginosa present in the nasal microbiome of COVID-19 patients, which may be responsible for other secondary infections.

24 May 2021

Leaky gut and microbial dysbiosis could contribute to cytokine storm in severely ill COVID-19 cases

The gut is a well-established route of infection and target for viral damage by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19. This is supported by the clinical observation that about half of COVID-19 patients exhibit gastrointestinal (GI) symptoms.

8 Apr 2021

Research uncovers strategy to revert antibiotic-resistance in dangerous superbugs

A major risk of being hospitalized is catching a bacterial infection. Hospitals, especially areas including intensive care units and surgical wards, are teeming with bacteria, some of which are resistant to antibiotics - they are infamously known as ‘superbugs’.

18 Jan 2021

Toxic pesticide turned into treatment against antibiotic-resistant bacteria

N-Aryl-C-nitroazoles are an important class of heterocyclic compounds. They are used as pesticides and fungicides. However, these substances could be toxic to humans and cause mutations.

29 Dec 2020

Researchers focus on preventing infections caused by carbapenemase-producing bacteria

In 2017, the World Health Organization published a list of pathogens for which new drugs are urgently needed.

16 Dec 2020

Researchers develop new method to customize lysins for targeting unwanted bacteria

Researchers from the Antimicrobial Resistance Interdisciplinary Research Group at Singapore-MIT Alliance for Research and Technology, MIT's research enterprise in Singapore, have developed a method to produce customizable engineered lysins that can be used to selectively kill bacteria of interest while leaving others unharmed.

1 Dec 2020

Special formulation of inhaled niclosamide may be effective against SARS-CoV-2

Now in new research published on the preprint server bioRxix*, a novel formulation of the drug Niclosamide (NIC) is observed to be effective against SARS-CoV-2 and MERS-CoV in mouse models; it also protects against methicillin-resistance Staphylococcus aureus pneumonia and inflammatory lung damage.

28 Sep 2020

Drug resistance may be reversed using hydrogen sulphide

Antibiotic resistance in some kinds of bacteria may be reversed using hydrogen sulphide (H2S), according to a new study.

24 Aug 2020